| Autor: |
Excoffon KJDA; Spirovant Sciences, Inc, Philadelphia, Pennsylvania, USA., Smith MD; Spirovant Sciences, Inc, Philadelphia, Pennsylvania, USA., Falese L; Spirovant Sciences, Inc, Philadelphia, Pennsylvania, USA., Schulingkamp R; Spirovant Sciences, Inc, Philadelphia, Pennsylvania, USA., Lin S; Spirovant Sciences, Inc, Philadelphia, Pennsylvania, USA., Mahankali M; Spirovant Sciences, Inc, Philadelphia, Pennsylvania, USA., Narayan PKL; Spirovant Sciences, Inc, Philadelphia, Pennsylvania, USA., Glatfelter MR; Spirovant Sciences, Inc, Philadelphia, Pennsylvania, USA., Limberis MP; Spirovant Sciences, Inc, Philadelphia, Pennsylvania, USA., Yuen E; Spirovant Sciences, Inc, Philadelphia, Pennsylvania, USA., Kolbeck R; Spirovant Sciences, Inc, Philadelphia, Pennsylvania, USA. |
| Abstrakt: |
Cystic fibrosis (CF) is a serious genetic disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. Approved small molecule therapies benefit the majority of people with CF (pwCF), but unfortunately not all. Gene addition offers a mutation agnostic treatment option for all pwCF. SP-101 is an adeno-associated virus gene therapy vector (AAV2.5T) that has been optimized for efficient human airway cell transduction, and that contains a functional and regulated shortened human CFTR minigene ( hCFTRΔR ) with a small synthetic promoter/enhancer. To understand SP-101 airway distribution, activity, and the associated immune response, in vivo studies were performed in wild-type and CF ferrets. After single dose inhaled delivery of SP-101, followed by single dose inhaled doxorubicin (an AAV transduction augmenter) or saline, SP-101 vector genomes were detected throughout the respiratory tract. hCFTRΔR mRNA expression was highest in ferrets also receiving doxorubicin and persisted for the duration of the study (13 weeks). Pre-existing mucus in the CF ferrets did not present a barrier to effective transduction. Binding and neutralizing antibodies to the AAV2.5T capsid were observed regardless of doxorubicin exposure. Only a portion of ferrets exhibited a weak T-cell response to AAV2.5T and no T-cell response was seen against hCFTRΔR. These data strongly support the continued development of inhaled SP-101, followed by inhaled doxorubicin, for the treatment of CF. |
